Well, we are expecting the president to announce a drug pricing deal with Fizer any minute now. That's according to two people familiar with those plans. Now, we're looking for three things in particular, and that's according to one person familiar with what we're expecting. So, first, we're expecting that Fiser will agree to lower prices in Medicaid.We're also expecting a three-year exemption from tariffs on the condition that Fizer builds more in the US. And the third thing is that Fizer will agree to sel ...

may have noticed uh some of the pharmaceutical names have moved up sharply in the last few minutes. We've got some breaking news out of Washington on drug pricing. Aean Jabers has the details perhaps filling us in on why we've seen this move.Aean. Yeah, David. It is pharmaceutical related.Uh and we don't have all the details right now. We're trying to solve a mystery in real time here, which is that the president has an event on his calendar at 11:00 a. m.just scheduled as an announcement. Uh and the questi ...

Core Points - The announcement from the White House is related to pharmaceutical pricing, specifically involving a deal with a major pharmaceutical company [3][4][5] - The agreement reportedly includes discounted prices for Medicaid and a three-year reprieve on tariffs for products manufactured in the United States [3][5] - The company involved in the deal is speculated to be Pfizer, although this has not been officially confirmed by the White House [4][5][7] Pharmaceutical Industry Impact - The initiative aims to lower drug prices across the board, aligning with the president's goal to address pharmaceutical pricing as a significant issue during his presidency [5] - The program may be branded as "Trump RX," allowing consumers to purchase certain medications directly from a government website [6][7] - There is uncertainty regarding the participation of other pharmaceutical companies and the implications for individuals already on Medicare or Medicaid [7]

Watch live coverage as President Trump announces a deal with Pfizer on lowering drug prices. For more context and news coverage of the most important stories of our day, click here: https://www.nbcnews.com » Subscribe to NBC News: http://nbcnews.to/SubscribeToNBC » Watch more NBC video: http://bit.ly/MoreNBCNews NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Night ...

Drug Pricing Pressures & Industry Response - Pharma companies are expected to submit plans to the Trump administration for voluntarily lowering drug prices [1] - Most companies are in talks with the administration but haven't made concrete promises yet [1] - The industry's main lobbying group will create a new direct-to-consumer (DTC) website aggregating medicines from member companies at lower prices [4] - HHS sent a proposed drug pricing pilot program to the White House for review [4] Strategies to Lower Drug Costs - Some companies agree that other countries should pay more for drugs [2] - Bristol Myers Squibb is making its psoriasis drug to tick 2 available at more than 80% below the list price [3] - Setting up a DTC website is one way to cut prices, for example, Bristol drug can cut the price by 80% [6] Challenges & Perspectives - Companies can't easily raise prices in places like Europe due to existing controls [2][3] - Even with price cuts, some drugs can still cost consumers $16,000 per year out of pocket [6] - Companies argue that insurance needs to be fixed, with better drug coverage and lower co-pays [7] - Drug companies are trying to shift blame to the middleman [5]

This Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing https://t.co/a1bmbDi1RS ...

Core Viewpoint - Investors are increasingly concerned about the lack of clarity regarding drug pricing, which is creating uncertainty in the market [1] Group 1 - The ambiguity in drug pricing is causing unease among investors [1] - This uncertainty may impact investment decisions and market stability [1]

Joining us now, Courtney Breen, senior analyst at Bernstein, covering US Pharma, Bioarma. Courtney, great to have you with us. Um, obviously there's still some some questions outstanding.I'm I'm wondering if you're you know, as you think about companies with US manufacturing, if companies have pre-existing plants, are they also exempt. I think what we've had so far is a a tweet or a post uh on on truth social rather than necessarily the discreet and detailed policy. So I think there are a lot of questions t ...

This Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing https://t.co/a1bmbDi1RS ...

This Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricinghttps://t.co/OqK5Yd7WE1 https://t.co/eBccIgcbgG ...